The Use of Metformin as Primary Prevention of Major Adverse Cardiac Events in Euglycemic Patients

مرکز و کتابخانه مطالعات اسلامی به زبان های اروپایی

منو

" The Use of Metformin as Primary Prevention of Major Adverse Cardiac Events in Euglycemic Patients "
Campbell, Shannon LaScalea, Keith

Document Type	:	Latin Dissertation
Language of Document	:	English
Record Number	:	1114226
Doc. No	:	TLpq2404660144
Main Entry	:	Campbell, Shannon
	:	LaScalea, Keith
Title & Author	:	The Use of Metformin as Primary Prevention of Major Adverse Cardiac Events in Euglycemic Patients\ Campbell, ShannonLaScalea, Keith
College	:	Weill Medical College of Cornell University
Date	:	2020
student score	:	2020
Degree	:	M.S.
Page No	:	46
Abstract	:	Problem: Cardiovascular disease is one of the top causes of mortality worldwide. Currently, there are methods in place that range from dietary modification and exercise to statin therapy for primary and secondary prevention. An alternative therapy for patients who do not yet qualify for statin therapy is needed to minimize the risk of disease. Metformin may be a putative solution for this gap in preventative care. Purpose: The purpose of this study is to evaluate levels of inflammation, central adiposity and overall adverse outcomes following metformin administration. Methods: Following an extensive literature review, the following study design is proposed. The study will recruit patients aged 30-65 years with at least two risk factors of cardiovascular disease. Participants on aspirin or statin therapy will be excluded as well as those with known history of diabetes mellitus type 1 or 2. Participants will start at 250 mg metformin twice a day and their dosage will increase to 500 mg twice daily after the medication is deemed well-tolerated. Outcomes: Participants will be followed every three to every six months for a total of five years. Serologic testing including CRP and IL-6 will be measured each visit. Additionally, weight and waist circumference will be measured. Participants will be assessed for adverse outcomes or other concurrent medical problems. Benefit: An additional method for primary prevention of cardiovascular disease can have a large impact on the health of the population by decreasing morbidity and mortality. Metformin can reduce many of the known factors that predispose individuals to heart disease such as central adiposity and inflammation.
Subject	:	Adverse cardiac events
	:	Euglycemic patients
	:	Health sciences
	:	Metformin